
	Where results make sense

Topic: Remicade

Related Topics

Sadness

Wasserman test

Mouse

Feynman

Bable

All India Institute of Medical Sciences

Bokhoven

Sumerian

Nyonya

Whinmoor

Quarth

New Carlisle, Ohio

Mazda T platform

IOP

Medal of Honor

In the News (Fri 25 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Press - Centocor Announces FDA Acceptance of Supplimental Biologics License Application for Remicade ® to Treat ...
		REMICADE is a monoclonal antibody that specifically targets and irreversibly binds to tumor necrosis factor-alpha (TNF-a) on the cell membrane and in the blood.
		REMICADE is the only biologic indicated for the treatment of patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
		REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn’s disease.
	www.spondylitis.org /press/remicade.aspx (1089 words)

	Remicade(R) Approved In Australia For Treatment Of Early Rheumatoid Arthritis And Psoriatic Arthritis
		For patients with Crohn's disease, REMICADE is indicated in the treatment of moderate to severe disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have inadequate response to conventional therapies.
		REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with Crohn's disease.
		REMICADE was approved for early RA in the European Union (EU) in June 2004.
	www.medicalnewstoday.com /medicalnews.php?newsid=40268 (2430 words)

	Remicade
		REMICADE is now approved for children (ages 6 to 17) with moderate to severe Crohn's disease who haven't responded well to other therapies.
		REMICADE has been proven to reduce the signs and symptoms of Crohn’s disease and induce and maintain remission in patients with moderate to severe Crohn's whose disease is still active despite treatment with other therapies.
		REMICADE is the first and only treatment approved for moderate to severe Crohn's disease in adults-and-children who haven't responded well to other therapies.
	www.remicade-crohns.com (304 words)

	FDA Approves Remicade For Crohn's Disease (Site not responding. Last check: )
		Remicade, formerly known as Avakine, is the first of a new class of agents that blocks activity of a key biologic response mediator called tumour necrosis factor alpha (TNF-alpha).
		Remicade is indicated for treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy.
		Remicade was also shown to be effective in reducing the number of open, draining fistulas, a painful complication of Crohn's disease in which deep openings burrow from the bowel wall through the surface of the skin, causing drainage of mucous and/or fecal material.
	www.pslgroup.com /dg/ab48e.htm (711 words)

	News - FDA Approves Remicade(R) (Infliximab) for Treatment of Chronic Severe Plaque Psoriasis
		Remicade is the only biologic indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately-to-severely active CD who have had an inadequate response to conventional therapy.
		Additionally, in September 2005, Remicade was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
		Remicade can lower your ability to fight infections, so if you are prone to or have a history of infections, or develop any signs of an infection such as fever, fatigue, cough, flu or warm, red or painful skin while taking Remicade, tell your doctor right away.
	www.docguide.com /news/content.nsf/news/852571020057CCF6852571F600585763 (2530 words)

	Data Sheet
		REMICADE is indicated for treatment of moderate to severe, active Crohn's disease in children, aged 6 to 17 years, who have not responded to a full and adequate course of conventional therapy, or who are intolerant to or have medical contraindications to such therapy.
		REMICADE is indicated for reducing signs and symptoms of psoriasis and improving quality of life in patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate.
		REMICADE treatment is to be administered under the supervision of specialised physicians experienced in the diagnosis and treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or psoriasis, or inflammatory bowel diseases.
	www.medsafe.govt.nz /profs/Datasheet/r/Remicadeinj.htm (11462 words)

	products (Site not responding. Last check: )
		REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.
		REMICADE is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
		REMICADE is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
	www.centocor.com /biomedicines/products.jsp (1437 words)

	Remicade - det första godkända biologiska läkemedlet inom EU för behandling av tarmsjukdomen ...
		Remicade är det första biologiska läkemedel som godkänns för behandling av ulcerös kolit av måttlig till svår karaktär.
		I båda studierna fick patienterna antingen placebo eller Remicade 5 mg/kg eller 10 mg/kg vid vecka 0, 2, 6 och var åttonde vecka fram till vecka 22.
		Remicade är en anti-TNF-antikropp, som kan förhindra de skadliga effekterna av TNF-alfa och som avbryter den inflammatoriska processen.
	www.lif.se /cs/default.asp?CS_nyhetskategorilistaSortField=NewsArkivet&CS_nyhetskategorilistaPageNo=9&id=5889&ptid= (817 words)

	gihealth.com - built for patient satisfaction
		Because Remicade blocks TNF in Crohn's patients, it is sometimes called an "anti-TNF antibody." Remicade was approved by the FDA in May 1998 for treatment of Crohn's disease.
		Remicade is currently reserved for patients with active signs and symptoms of Crohn's disease who fail to adequately control their disease with convential therapy - prednisone, Pentasa, Asacol, Imuran, etc.
		Remicade works best in reducing active inflammation, but has little effect on scar tissue which may be permanent.
	www.gihealth.com /html/education/drugs/remicade.html (1424 words)

	LCD for Remicade (Infliximab) (L9686) (Site not responding. Last check: )
		Remicade™ is a chimeric monoclonal antibody that binds to tumor necrosis factor alpha (TNFa), which is believed to be critical to the human body's reaction to inflammation.
		Remicade™ is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.
		REMICADE™, in combination with methotrexate, is indicated for reducing signs and symptoms and inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.
	www.cignamedicare.com /partb/lmrp_lcd/nc/cms_fu/2001-005-04.html (1899 words)

	Remicade Information from Drugs.com
		Remicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis (Crohn's disease), and ankylosing spondylitis.
		Remicade is not for use in children younger than 6 years old.
		Remicade is given as an injection through a needle placed into a vein.
	www.drugs.com /remicade.html (1465 words)

	FDA Approves Remicade for Children with Crohn's Disease
		Remicade is a genetically engineered monoclonal antibody, which reduces inflammation (swelling/redness) by blocking the action of tumor necrosis factor-alpha (TNF-α), that was initially approved in 1998 to treat Crohn's disease in adults.
		"Remicade is not a cure, but it provides a much-needed option for reducing the symptoms and inducing and maintaining disease remission in children who have no other safe and effective therapy," he said.
		The safety and effectiveness of Remicade in pediatric Crohn's disease were assessed in a randomized study in 112 children who were 6 to 17 years old with moderately to severely active Crohn's disease who had an inadequate response to conventional therapies.
	www.fda.gov /bbs/topics/NEWS/2006/NEW01376.html (440 words)

	Remicade Indications & Dosage
		REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.
		REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn?s disease who have had an inadequate response to conventional therapy.
		REMICADE is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure inpatients with fistulizing Crohn?s disease.
	www.healthcentral.com /druglibrary/408/remicade-indications_dosage.html (379 words)

	Remicade (Site not responding. Last check: )
		Remicade is a medication that interferes with the action of TNF (tumor necrosis factor).
		Remicade is a “second line” drug in the treatment of rheumatoid arthritis and as such, is reserved for persons with severe arthritis who have not responded to other medications.
		The safety of taking Remicade during pregnancy and breast feeding is unknown, and unless a physician specifically recommends otherwise, it should be avoided during pregnancy and breast feeding.
	www.midwestarthritis.com /html/remicade.htm (756 words)

	Remicade, Remicade Side Effects, Remicade Warning, Remicade Lawsuit, Remicade Death
		Remicade (Inflixmab) is an immune-suppressing product manufactured by Centocor, a wholly owned subsidiary of Johnson and Johnson, which has been approved by the FDA for the use of treating Crohn's disease and rheumatoid arthritis.
		Specifically, Remicade, in combination with Methotrexate, is indicated for use in patients with moderately to severely active Crohn’s disease which have had an inadequate response to conventional therapy and for the treatment of patients with fistulizing Crohn’s disease.
		n October 18, 2001 a second drug warning was sent to healthcare professionals warning them not to initiate Remicade therapy in patients with congestive heart failure, to discontinue Remicade in patients whose congestive heart failure is worsening and to consider discontinuing Remicade in patients with stable congestive heart failure.
	www.ennislaw.com /remicade.html (593 words)

	Newly Approved Drug Therapies (703): Remicade (infliximab), Centocor
		The FDA has approved Remicade, in combination with methotrexate, for inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate.
		Remicade was previously approved in 1999 for the treatment of signs and symptoms of rheumatoid arthritis in individuals who have not had success with methotrexate treatment.
		Remicade was evaluated in a multicenter phase III trial called ATTRACT (Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy), which included 428 subjects at 34 centers in North America and Europe.
	www.centerwatch.com /patient/drugs/dru703.html (506 words)

	Missouri Remicade Attorneys – Defective Drugs Lawyer, Infliximab, Rheumatoid Arthritis, Tuberculosis
		Did you know: If you have taken Remicade and you have suffered from an infection, including sepsis or tuberculosis, you may be entitled to compensation.
		Remicade (Infliximab) is an immune-suppressing drug used to treat rheumatoid arthritis and Crohn's disease.
		If you or a family member has been harmed by Remicade, our attorneys will use every resource at their command to make sure you are compensated for this injustice.
	www.brownandcrouppen.com /remicade.html (546 words)

	IBD Section - web magazine - medicinali speciale REMICADE / INFLIXIMAB
		REMICADE is indicated for the reduction in signs and symptoms of Crohn's disease in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.
		REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadeguate response to methotrexate.
		REMICAD is indicated for the reduction in signs and symptoms of Crohn's disease in patients with moderately to severely active Crohn's disease who have an inadeguate response to conventional therapy.
	www.geocities.com /gp_mason/MICI_notiziario_remicade.html (8354 words)

	PRESS RELEASE FDA Approves REMICADE(R) for Ninth Indication: Psoriatic Arthritis (Site not responding. Last check: )
		REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both RA and Crohn's disease in North America, the EU and Japan.
		REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing CD.
		REMICADE can lower your ability to fight infections, so if you are prone to or have a history of infections, or develop any signs of an infection such as fever, fatigue, cough, or the flu while taking REMICADE, tell your doctor right away.
	www.marketwire.com /mw/release_html_b1?release_id=86869 (1933 words)

	PRESS RELEASE REMICADE Data Show Promise for Children Afflicted With Crohn's Disease (Site not responding. Last check: )
		REMICADE has received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active pediatric Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract that affects nearly 100,000 children under the age of 18 in the United States.
		Additionally, REMICADE was recently approved for the treatment of moderately to severely active ulcerative colitis (another type of inflammatory bowel disease) in patients who have had an inadequate response to conventional therapy.
		REMICADE is the only biologic indicated for the treatment of patients with moderately to severely active CD who have had an inadequate response to conventional therapy.
	www.marketwire.com /mw/release_html_b1?release_id=99064 (1935 words)

	Remicade Liver Failure Side Effects Hepatic Damage
		In August of 1998, Remicade was approved for the treatment of Crohn’s disease.
		Remicade controls the pain associated with rheumatoid arthritis, the chronic inflammation in the lining of the joints and the pain from Crohn's disease, an intestinal disease.
		You may have a Remicade lawsuit and be entitled to compensation for your injuries.
	www.1800theeagle.com /topics/Remicade.html (351 words)

	Remicade Arthritis Medicine - Study: Remicade eases arthritis pain
		Remicade maintenance therapy also resulted in the inhibition of structural damage and significant improvements in functional status and quality of life as maintained over the course of one year.
		Remicade is currently indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.
		At week 54, median improvement from baseline in PCS and MCS in the Remicade group was 7.4 and 2.8, respectively, and the median improvement in the placebo/Remicade group, the group of patients initially receiving placebo and crossed over to Remicade by week 24, was 10.2 and 1.9, respectively.
	www.dentalplans.com /Dental-Health-Articles/Study-Remicade-eases-arthritis-pain.asp (1063 words)

	Long-Term Remicade Use Helps Crohn's
		Remicade has shown promise in providing relief in reducing the symptoms of Crohn's disease, which is a lifelong inflammatory disorder of the intestines.
		Remicade is commonly used in multiple doses for rheumatoid arthritis.
		Patients on steroids who took Remicade as a "maintenance" drug were able to reduce or -- in one-third of cases -- able to stop taking steroids altogether and still get relief from symptoms.
	www.webmd.com /content/article/24/1820_50558.htm (337 words)

	Remicade / Infliximab Lawsuit Information - Find Trial Lawyers and Attorneys with Experience in Remicade / Infliximab ...
		Remicade (infliximab), a drug manufactured by Johnson & Johnson subsidiary Centocor, is used to treat arthritis.
		In addition to infection concerns, the FDA recently warned that Remicade use by patients suffering from congestive heart failure may be dangerous.
		On August 15, 2001, Centocor announced that the company was adding a so-called "fl box warning" to Remicade's label in order to better inform doctors and patients of the increased chance of developing tuberculosis while taking the drug.
	www.injuryboard.com /view.cfm/Topic=825 (684 words)

	Remicade and Lymphoma Risk
		Those Remicade users who are severely ill or who were exposed to drug therapies that suppress the immune system are at the highest risk.
		The rate of lymphoma was three times higher in rheumatoid arthritis patients taking Remicade than in the general population, and six times higher for those in the Crohn’s disease/rheumatoid arthritis group taking Remicade than in the general population.
		Remicade is not related to the arthritis drug, Vioxx, a type of medication known as a COX–2 inhibitor that has been linked to an increased risk of heart attacks and strokes.
	www.braytonlaw.com /news/mednews/110504_remicade.htm (490 words)

Try your search on: Qwika (all wikis)